BOSTON, MA – December 1, 2025 – Intrinsic Therapeutics, Inc., a medical technology company redefining the standard of care for lumbar discectomy patients with large annular defects, today announced that Joel D. Siegal, MD, of Key Clinics in Galion, OH, has achieved the distinction of Barricaid Gold Center of Excellence. This designation honors consistent clinical excellence and a sustained commitment to optimizing outcomes for high-risk discectomy patients with Barricaid, which has been shown to reduce reoperations for reherniations by 81%*.
“Dr. Siegal’s achievement reflects an unwavering dedication to patient care and surgical precision,” said Jake Tanner, VP of Marketing at Intrinsic Therapeutics. “His consistent use of Barricaid as part of a comprehensive surgical strategy demonstrates how thoughtful adoption of advanced technology can meaningfully improve patient outcomes.”
The Barricaid is a bone-anchored annular closure device designed to close lumbar annular defects following limited discectomy. By addressing the defect during surgery, Barricaid is clinically proven to lower the risk of reherniation and reoperation, helping patients return to their lives with greater confidence. The Barricaid Center of Excellence program identifies and supports high-performing clinical teams that are advancing patient outcomes through the utilization of the Barricaid device.
“I’m deeply honored to receive this Gold Center of Excellence designation,” said Dr. Joel D. Siegal. “This recognition reflects the commitment of our entire team to evidence-based care and to continuously improving how we serve our patients. Barricaid has become an important tool in helping us protect patients from reherniation and deliver durable, positive results.”
About Barricaid®
Barricaid is a proprietary technology designed to prevent reherniation and reduce the risk of reoperation in patients with large annular defects following lumbar discectomy surgery. Barricaid has been implanted in more than 13,000 patients and is supported by clinical studies across eight distinct patient populations, including two randomized controlled trials and six single-arm studies. A multicenter, Level I RCT demonstrating superior outcomes compared to discectomy alone was published in JAMA with five-year follow-up results.
*Some studies are outside FDA indications. Values at a minimum of 1-year post-op. Minimum study size: 20 Barricaid subjects.
Barricaid is a registered trademark of Intrinsic Therapeutics, Inc.